



# 7

Patent  
Attorney's Docket No. 033352-010

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Cruz, et al.

Application No.: 09/978,309

Filed: October 15, 2001

For: Compositions and Methods for Treating  
Cellular Response to Injury and Other  
Proliferating Cell Disorders Regulated by  
Hyaladherin and Hyaluronans

Group Art Unit: 1653

Examiner: Unassigned

RECEIVED  
FEB 26 2002  
TECH CENTER 1600/2300INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTERAssistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the  
above-identified patent application.


- ☒ [x] No additional fee for submission of an IDS is required.
- ☐ [ ] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ [ ] A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ [ ] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth  
in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ [ ] Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ [ ] A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R.  
§§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to  
Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER &amp; MATHIS, L.L.P.

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300By: Mary Ann Dillahunty  
Mary Ann Dillahunty  
Registration No. 34,576Date: February 15, 2002



Patent  
Attorney's Docket No. 033352-010

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
)  
Cruz, et al. ) Group Art Unit: 1653  
)  
Application No.: 09/978,309 ) Examiner: Unassigned  
)  
Filed: October 15, 2001 )  
)  
For: Compositions and Methods for Treating )  
Cellular Response to Injury and Other )  
Proliferating Cell Disorders Regulated by )  
Hyaladherin and Hyaluronans )

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56,  
Applicants hereby submit the following information in conformance with 37 C.F.R.  
§§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited  
below is enclosed.

1.	RE32,011	10/22/85	Zimmerman et al.
2.	4,018,884	4/19/77	Cleeland, Jr. et al.
3.	4,359,535	11/16/82	Pieczenik
4.	4,376,110	3/8/83	David et al.
5.	4,411,993	10/25/83	Gillis
6.	4,486,530	12/4/84	David et al.
7.	4,528,266	7/9/85	Pieczenik
8.	4,543,439	9/24/85	Frackelton, Jr. et al.
9.	4,551,433	11/5/85	DeBoer
10.	4,603,112	7/29/86	Paoletti et al.
11.	4,736,866	4/12/88	Leder et al.

**RECEIVED**  
**FEB 26 2002**  
**TECH CENTER 1600/2900**

12.	4,744,981	5/17/88	Pavanasasivam
13.	4,745,051	5/17/88	Smith et al.
14.	4,769,330	9/6/88	Paoletti et al.
15.	4,816,567	3/28/89	Snyder et al.
16.	4,851,341	7/25/89	Hopp et al.
17.	4,870,009	9/26/89	Evans et al.
18.	4,873,191	10/10/89	Wagner et al.
19.	4,897,255	1/30/90	Fritzberg et al.
20.	4,902,614	2/20/90	Wakabayashi et al.
21.	4,987,071	1/22/91	Cech et al.
22.	4,988,496	1/29/91	Srinivasan et al.
23.	5,017,487	5/21/91	Stunnenberg et al.
24.	5,087,571	2/11/92	Leder et al.
25.	5,091,309	2/25/92	Schlesinger et al.
26.	5,106,951	4/21/92	Morgan, Jr. et al.
27.	5,110,833	5/5/92	Mosbach
28.	5,166,057	11/24/92	Palese et al.
29.	5,162,215	11/10/92	Bosselman et al.
30.	5,169,784	12/8/92	Summers et al.
31.	5,175,383	12/29/92	Leder et al.
32.	5,175,384	12/29/92	Krimpenfort et al.
33.	5,204,244	4/20/93	Fell et al.
34.	5,217,879	6/8/93	Huang et al.
35.	5,219,740	6/15/93	Miller et al.
36.	5,221,778	6/22/93	Byrne et al.
37.	5,225,539	7/6/93	Winter
38.	5,242,687	9/7/93	Fernandez-Pol
39.	5,243,041	9/7/93	Tykocinski et al.
40.	5,254,678	10/19/93	Haseloff et al.

41.	5,266,317	11/30/93	Tomalski et al.
42.	5,288,514	2/22/94	Ellman
43.	5,288,641	2/22/94	Roizman
44.	5,328,834	7/12/94	Ngo et al.
45.	5,359,051	10/25/94	Cook et al.
46.	5,387,742	2/7/95	Cordell
47.	5,347,075	9/13/94	Sorge
48.	5,395,750	3/7/95	Dillon et al.
49.	5,463,564	10/31/95	Agrafiotis et al.
50.	5,482,856	1/9/96	Fell, Jr. et al.
51.	5,506,337	4/9/96	Summerton et al.
52.	5,545,808	8/13/96	Hew et al.
53.	5,567,607	10/22/96	Zhao et al.
54.	5,580,859	12/3/96	Felgner et al.
55.	5,591,624	1/7/97	Barber et al.
56.	5,633,076	5/27/97	DeBoer et al.
57.	5,693,761	12/2/97	Queen et al.
58.	5,693,762	12/2/97	Queen et al.
59.	5,698,435	12/16/97	Robinson et al.
60.	5,716,613	2/10/98	Guber et al.
61.	5,716,826	2/10/98	Gruber et al.
62.	5,716,832	2/10/98	Barber et al.
63.	5,741,957	4/21/98	Deboer et al.
64.	5,770,380	6/23/98	Hamilton et al.
65.	5,780,009	7/14/98	Karatzas et al.
66.	5,780,225	7/14/98	Karatzas et al.
67.	5,789,245	8/4/98	Dubensky, Jr. et al.
68.	5,814,482	9/29/98	Dubensky, Jr. et al.
69.	5,817,491	10/6/98	Yee et al.

70.	5,843,723	12/1/98	Dubensky, Jr. et al.
71.	5,851,529	12/22/98	Guber et al.
72.	5,840,479	11/24/98	Little et al.
73.	5,849,288	12/15/98	Reisner
74.	5,872,005	2/16/99	Wang et al.
75.	EP 0360 257	11/13/96	
76.	EP 0415 731	3/6/91	
77.	EP 044 0219	8/7/91	
78.	EP 0612844 (A2)	8/31/94	
79.	WO 89/01973	3/9/89	
80.	WO 90/02809	3/22/90	
81.	WO 90/07862	7/26/90	
82.	WO 90/07936	7/26/90	
83.	WO 91/00285	1/10/91	
84.	WO 92/06693	4/30/94	
85.	WO 92/15677	9/17/92	
86.	WO 92/15679	9/17/92	
87.	WO 93/10218	5/27/93	
88.	WO 93/11230	6/10/93	
89.	WO 93/12227	6/24/93	
90.	WO 93/20242	10/14/93	
91.	WO 93/25234	12/23/93	
92.	WO 93/25698	12/23/93	
93.	WO 94/03622	2/17/94	
94.	WO 95/02566	1/26/95	
95.	WO 95/04277	2/9/95	
96.	WO 95/10607	4/20/95	
97.	WO 95/12387	5/11/95	
98.	WO 95/16209	6/15/95	

99. WO 95/16712 6/22/95
100. WO 95/16918 6/22/95
101. WO 95/24186 9/14/95
102. WO 95/24929 9/21/95
103. WO 95/30642 11/16/95
104. WO 96/00148 1/4/96
105. WO 97/38098 10/16/97
106. WO 99/01164 1/14/99:
107. Bauer, et al., "A genetic enrichment for mutations constructed by oligodeoxynucleotide-directed mutagenesis", *Gene*, 37:73-81, (1985).
108. Bird, et al., "Single-chain antigen-binding proteins", *Science*, 242:423-426, (1988).
109. Brinster, et al., "Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs", *Proc. Natl. Acad. Sci. U.S.A.*, 82:4438-4442, (1985).
110. Chothia, et al., "Domain association in immunoglobulin molecules", *J. Mol. Biol.*, 186:651, (1985).
111. Craik, et al., "Use of Oligonucleotides for site-specific mutagenesis", *BioTechniques*, pp. 12-19, (Jan. 1985).
112. Curiel, et al., "High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes", *Hum. Gene Ther.*, 3:147-154, (1992).
113. Drinkwater, et al., "Chemically induced mutagenesis in a shuttle vector with a low-background mutant frequency", *PNAS*, 83:3402-3406, (1986).
114. Fisher-Hoch, et al., "Protection of rhesus monkeys from fata Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene", *PNAS*, 86:317-321, (1989).
115. Flexner, et al., "Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2", *Vaccine*, 8:17-21, (1990).
116. Flexner, et al., "Vaccinia virus expression vectors", *Ann. N.Y. Acad. Sci.*, 569:86-103, (1989).
117. Forster, et al., "Self-cleavage of plus and minus RNAs of virusoid and a structural model for the active sites", *Cell*, 48:211-220, (1987).


118. Hammer, et al., "Production of transgenic rabbits, sheep and pigs by microinjection", *Nature*, 315:680-683, (1985).
119. Haseloff, J., et al., "Simple RNA enzymes with new and highly specific endoribonuclease activities", *Nature*, 334:585-591, (1988).
120. Hirashima, et al., "A new immune system against viral infection using antisense RNA: micRNA-immune system", *Molecular Biology of RNA: New Perspectives*, Academic Press, San Diego, CA, pp. 401-412, (1987).
121. Hopp, et al., "A short polypeptide marker sequence useful for recombinant protein identification and purification", *Bio/Technology*, 6:1204-1210, (1988).
122. Horwitz, et al., "Selection of new biological activities from random nucleotide sequences: evolutionary and practical considerations", *Genome*, 3:112-117, (1989).
123. Huse, et al., "Generation of large combinatorial library of the immunoglobulin repertoire in phage lambda", *Science*, 246:1275-1281, (1989).
124. Inman, J., "Covalent linkage of functional groups, ligands, and proteins to polyacrylamide beads", *Methods In Enzymology*, Vol. 34, *Affinity techniques, Enzyme Purification: Part B*, pp. 31-59, Jakoby and Wilcheck (eds.), Academic Press, New York, (1974).
125. Jones, et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", *Nature*, 321:522-525, (1986).
126. Kit, *Adv. Exp. Med. Biol.*, 215:219-236 (1989).
127. Kohler, et al., "Continuous cultures of fused cells secreting antibody of predefined specificity", *Nature*, 256:495-497, (1975).
128. Kyte, et al., "A simple method for displaying the hydropathic character of a protein", *J. Mol., Biol.*, 157:105-132, (1982).
129. Liao, et al., "A simple high-efficiency method for random mutagenesis of cloned genes using forced nucleotide misincorporation", *Gene*, 88:107-111, (1990).
130. Look, et al., "The Identification of Cyclooxygenase-1 Inhibitors from 4-Thiazolidinone Combinatorial Libraries," *Bioorg and Med. Chem. Letters*, 6:707-712, (1996).
131. Luytjes, et al., "Amplification, express, and packaging of a foreign gene by influenza virus", *Cell*, 59:1107-1113, (1989).

132. Mastronardi, et al., "Demyelination in a transgenic mouse: a model for multiple sclerosis", *J. Neurosci. Res.*, (93), Vol. 36, pp. 315-324.
133. Morrison, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains", *Proc. Natl. Acad. Sci. U.S.A.*, 81:6851-6855, (1984).
134. McMichael, et al., "Cytotoxic t-cell immunity to influenza", *N. Eng. J. Med.*, 309: 13-17, (1983).
135. Mulligan, et al., "Synthesis of rabbit- $\beta$ -globin in cultured monkey kidney cells following infection with a SV40  $\beta$ -globin recombinant genome", *Nature*, 277:108-114, (1979).
136. Novotny et al., "Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers" *Proc. Natl. Acad. Sci. U.S.A.*, 82:4592-4596, (1985).
137. Palmiter, et al., "Metallothionein-human GH fusion genes stimulate growth of mice", *Science*, 222:809-814, (1983).
138. Palmiter, et al., "Transgenic mice", *Cell*, 41:343-345, (1985).
139. Phillips, et al., "Solid-phase Synthesis of Benzimidazoles," *Tet. Letters*, 37:4887-4890, (1996).
140. Poznansky, "Gene transfer into human lymphocytes by a defective human immunodeficiency virus type-1 vector", *J. Virol.*, 65:532-536, (1991).
141. Presta, L., "Antibody engineering", *Curr. Op. Struct., Biol.*, 2:593-596, (1992).
142. Reichmann, et al., "Reshaping human antibodies for therapy", *Nature*, 332:323-327 (1988).
143. Ruhland, et al., "Solid-supported Combinatorial Synthesis of Structurally Diverse Beta-Lactams", *J. Amer. Chem. Soc.*, 111:253-254, (1996).
144. Sastry, et al., "Cloning of immunological repertoire in *Escherichia coli* for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library:", *Proc. Natl. Acad. Sci. U.S.A.*, 86:5728-5732, (1989).
145. Scatchard, G., "The attractions of proteins for small molecules and ions", *Ann. N.Y. Acad. Scien.*, 51:660-672, (1949).



146. Stein, et al., "Antisense oligonucleotides as therapeutic agents-is the bullet really magical?", *Science*, 261:1004-1012, (1993).
147. Uhlenbeck, O., "A small catalytic oligoribonucleotide", *Nature*, 328:596-600, (1988).
148. von Heijne, "Signal sequences: the limits of variation", *J. Mol. Biol.*, 184:99-105, (1985).
149. Walbot, et al., "Plant development and ribozymes for pathogens", *Nature*, 334:196-197, (1988).
150. Walder, et al., "Oligodeoxynucleotide-directed mutagenesis using the yeast transformation system", *Gene*, 42:133-139, (1986).
151. Wang, et al., "The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression", *Clinical Cancer Research*, 4:567-576, (1998).
152. Wilchek, et al., "The Avidin-Biotin Complex in Bioanalytical Applications", *Anal. Biochem.*, 171:1-32, (1988).
153. Wu, et al., "Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements *in vivo*", *J. of Biol. Chem*, 264:16985-16987, (1989).
154. Yap, et al., *Nature*, 273:238-239, (1978).
155. Zaho, et al., "Influence of <sup>7</sup>Li on disease progression in murine models of diabetes: differences between NOD and obese mice", *Lithium*, 2(4), pp. 227-234, (1991).

The Examiner's attention is directed to copending application number 09/685,010 and 09/541,522 naming Cruz et al. as inventor(s) and filed on October 5, 2000 and April 3, 2000, respectively, and the documents cited therein, a copy of which is enclosed.

 In accordance with MPEP § 609(c)(2) (February 2000, page 600-107), the Office is requested to return a copy of this Information Disclosure Statement with the Examiner's initials adjacent to this paragraph indicating that this copending application has been considered. By citation to the copending application, confidentiality is not waived and the Office is requested to maintain the confidentiality of the copending application under 35 U.S.C. § 122.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees to Deposit Account No. 02-4800.

While this Information Disclosure Statement may contain "material" information pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to herein is "prior art" to the invention disclosed and claimed in the above-referenced application unless specifically designated as such.

Applicants specifically reserve the right, where appropriate, to antedate any such reference by the appropriate showing under 37 C.F.R. § 1.131 and § 1.608, or any other appropriate means.

To assist the Examiner, the documents are listed on the attached form PTO-1449.  
It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Mary Ann Dillahunty  
Mary Ann Dillahunty  
Registration No. 34,576

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300

Date: February 15, 2002